Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas by Melero, I. (Ignacio) et al.
Gene Therapy (1999) 6, 1779–1784
Ó 1999 Stockton Press All rights reserved 0969-7128/99 $15.00
http://www.stockton-press.co.uk/gt
BRIEF COMMUNICATION
Intratumoral injection of bone-marrow derived dendritic
cells engineered to produce interleukin-12 induces
complete regression of established murine
transplantable colon adenocarcinomas
I Melero, M Duarte, J Ruiz, B Sangro, JC Galofre´, G Mazzolini, M Bustos, C Qian and J Prieto
Departamento de Medicina Interna, Facultad de Medicina, Universidad de Navarra, C/Irunlarrea, 1, 31008 Pamplona, Spain
Stimulation of the antitumor immune response by dendritic required. The antitumor effect was inhibited by in vivo
cells (DC) is critically dependent on their tightly regulated depletion of CD8+ T cells and completely abrogated by sim-
ability to produce interleukin-12 (IL-12). To enhance this ultaneous depletion with anti-CD4 and anti-CD8 mAbs.
effect artificially, bone marrow (BM)-derived DC were gen- Mice which had undergone tumor regression remained
etically engineered to produce high levels of functional IL- immune to a rechallenge with tumor cells, showing the
12 by ex vivo infection with a recombinant defective aden- achievement of long-lasting systemic immunity that also
ovirus (AdCMVIL-12). DC-expressing IL-12 injected into was able to reject simultaneously induced concomitant
the malignant tissue eradicated 50–100% well established untreated tumors. Tumor regression was associated with
malignant nodules derived from the injection of two murine a detectable CTL response directed against tumor-specific
colon adenocarcinoma cell lines. Successful therapy was antigens probably captured by DC artificially released
dependent on IL-12 transfection and was mediated only by inside tumor nodules. Our results open the possibility of
syngeneic, but not allogeneic BM-derived DC, indicating similarly treating the corresponding human malignancies.
that compatible antigen-presenting molecules were
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DC are specialized APC for T-lymphocytes that initiate
CD4- and CD8-mediated immune responses.1–3 Fuctional
DC can be differentiated in vitro from myeloid precursors
or peripheral blood monocytes in the presence of GM-
CSF and IL-4.4–6 Effective protection and therapy has
been achieved by adoptive transfer of DC cultures in
which tumor antigens have been artificially introduced
into their antigen-presenting pathways by a number of
procedures.5–11 Various groups have shown that ex vivo
infection of DC with recombinant adenovirus encoding
for tumor rejection antigens is one of the most efficient
systems for delivering tumor antigens and other trans-
genes into DC.12,13
Typical DC differentiated in culture with GM-CSF and
IL-4 are not yet fully matured and need further stimu-
lation to upregulate their immunostimulatory and anti-
gen-presenting capabilities,1–3 by increasing MHC
antigen-presenting molecules, membrane-bound
costimulatory molecules, and cytokine secretion. Matu-
ration is triggered by various bacterial products such as
LPS and DNA,14–16 cytokines such as TNFa and IL-117
and importantly, by activated T cells through CD40L–
CD40 interactions.18 Among the changes that occur in DC
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during maturation, the induction of IL-12 synthesis is
considered an absolute requirement for the activation of
the anti-tumor cellular immune response.19
Artificial gene transfer of IL-12 into DC or their precur-
sors has been used to enhance their ability to stimulate
T cells both in vivo and in vitro.20,21 An important limi-
tation in those studies was the low frequency of DC actu-
ally transfected with the IL-12 genes. We reasoned that
ex vivo infection of DC with defective recombinant aden-
ovirus would overcome such an obstacle by genetically
modifying most DC.
Accordingly, we derived DC cultures from lympho-
cyte-depleted bone marrow cell suspensions by culturing
them for 7 days with GM-CSF and IL-4 as described5,10
obtaining 70–90% purity according to the combined
immunostaining with mAb anti-MHC class II, CD11c,
CD80 and CD86 (data not shown). Cells in our cultures
of bone marrow-derived DC displayed a relatively imma-
ture phenotype which can be driven to full maturation
by LPS and CD40 ligation increasing the expression of
CD80 and CD86 whereas losing phagocytic activity.
To assess frequency of productive gene transfer into a
variety of cell types, we have described a recombinant
defective adenovirus encoding for b-galactosidase
(AdCMVLacZ),22 that was used to study the infectivity
and gene transfer of DC cultures with defective recombi-
nant adenoviruses. We infected the cells with AdCM-
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cells showing enzyme expression. As shown in Figure 1a,
a significant proportion of DC expressing b-galactosidase
activity were detected 48 h after infection at MOIs rang-
ing from 104 to 103. However very small percentage of
b-galactosidase+ cells were observed at lower MOIs, in
contrast to reports in which MOIs of 100 were effec-
tive.11,12 Repetition of the experiments with indepen-
dently titrated batches of AdCMVLacZ confirmed our
Figure 1 Recombinant adenovirus productively transduce gene
expression into BM-derived DC. Seven-day cultures of BM-derived DC
were infected with AdCMVLacZ (a) or AdCMVIL-12 (b) at the indicated
MOIs. Forty-eight hours after AdCMVLacZ infection percentage of b-
galactosidase+ cells was assessed by X-gal staining (a) and p70 IL-12 con-
centration in the supernatants of the DC infected with AdCMVIL-12 was
measured by ELISA (b). Results are the mean – s.e.m. of five (a) and three
(b) different experiments. BM-derived DC were obtained essentially as
described.5 Briefly, erythrocyte-free cell suspensions flushed out from the
long bones of the rear limbs of Balb/c mice were depleted of granulocytes,
T and B lymphocytes by treatment with a mAb cocktail containing anti-
CD4, anti-CD8, anti-Gr-1, anti-B220 (Pharmingen, San Diego, CA,
USA) and rabbit complement (Sigma, Madrid, Spain). Cells were sub-
sequently cultured in RPMI 1640 5% FCS containing recombinant GM-
CSF (1000 IU/ml) (Peprotech, London, UK) and 20 ng/ml of recombinant
mouse IL-4 (Peprotech) for 7 days. Purity of DC cultures was assessed
by FACS analysis upon staining with FITC conjugated anti-I-Ad, anti-
CD11c, anti-CD80, anti-CD86 (Pharmingen). X-gal staining was perfor-
med as described22 and p70 IL-12 determinations in the supernatant were
carried out with a commercial ELISA (Endogen, Woburn, MA, USA)
according to the manufacturer’s instructions. Defective recombinant aden-
ovirus AdCMVIL-12 and AdCMVLacZ were prepared and titered as
described.26
results. We also found that preincubation of the recombi-
nant adenovirus with lipofectamine decreased the MOI
needed to obtain similar percentage of transduction of
BM derived DC by approximately one log (data not
shown) as recently reported.23 Since sensitivity of the
assay to detect b-gal activity has been proposed to under-
estimate the actual number of transfected cells,24 subtle
differences in the detection threshold can explain the
quantitative differences among laboratories to estimate
the optimal MOI. In this regard, in accordance with our
transduction data, recent evidence shows that production
of adenovirally transduced IL-2 and IL-6 in DC greatly
increases in the MOI range between 103 and 104.25 Con-
sistently we got up to 90–100% transduction with AdCM-
VLacZ at MOI of 100 in various cell lines (data not
shown) indicating that DC are somehow more difficult
to infect with recombinant adenovirus. In our hands
infection of BM-derived DC at MOI of 3000 routinely
gave 60–80% transfection with AdCMVLacZ with less
than 10% loss of viability after 48 h in culture. Those were
therefore selected as our working conditions of infection.
Lipofectamine was not introduced in the protocols to
avoid additional complexity but it should be considered
an alternative to downsize adenovirus production
needs.23
We had generated a recombinant defective adenovirus
encoding both chains of murine IL-12 (p35 and p40) sep-
arated by a ribosomal entry site (IRES) under the tran-
scriptional control of the CMV promoter (AdCMVIL-
12).26 Intratumoral injections of AdCMVIL-12 have been
shown to induce a powerful, often curative CD8-
mediated immune response.26 As shown in Figure 1b,
infection with AdCMVIL-12 modified in vitro cultured
DC to express high levels (1362 pg/ml/106 DC) of the
IL-12 p70 heterodimer as detected in the supernatant of
infected DC cultured for 48 h. It was concluded that
AdCMVIL-12 could be a good tool to engineer BM-
derived DC to produce IL-12 in order to enhance their
immunostimulatory properties. We asked as to whether
IL-12 gene transduction made DC capable of unleashing
effective cellular immune responses against tumor anti-
gens when tranferred into the tumor nodules. In this
scenario, DC are not artificially loaded ex vivo with tumor
antigens and they need to capture and present tumor
antigens after being taken up from the neighboring
malignant tissue. Experiments were set up in two murine
models of colon adenocarcinoma: CT26 (Balb/c origin)
and MC38 (C57Bl/6 origin) which grow aggressively and
are considered poorly immunogeneic. As summarized in
Table 1, a single injection of 2.5 · 105 syngeneic BM-
derived DC, which had been infected ex vivo with
AdCMVIL-12, induced complete regressions in 84% of
the CT26-derived subcutaneous nodules and in 50% of
the MC38-derived s.c. tumor nodules when treated 7
days after innoculation of the malignant cells (mean
diameter of the nodules between 3 and 6 mm). When
similarly raised allogeneic, rather than syngeneic DC,
also infected with AdCMVIL-12 and secreting compara-
ble quantities of IL-12 were used, no significant anti-
tumor effect was observed, indicating that compatible
antigen presentation was required. Intratumoral injection
with transformed fibroblasts similarly infected with
AdCMVIL-12 did not show antitumor effect neither in a
syngeneic (Balb/c) nor allogeneic (C57Bl/6) setting.
Therefore properties of DC absent in transformed fibro-
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Table 1 Intratumoral injection of BM-derived DC infected with AdCMVIL-12 induces tumor regressiona
In vitro infectionb AdCMVIL-12 AdCMVLacZ None HBSS
Intratumoral treatmentc
Tumor Exp Syngeneic Allogeneic Fibroblastsd Syngeneic Syngeneic
DC DC DC DC
CT26 1 4/5 ND ND 0/5 1/5 0/4
2 4/6 0/5 0/5 1/5 0/5 0/5
3 8/8 0/4 0/5 1/5 0/5 0/8
MC38 1 3/6 0/5 0/5 0/5 0/5 0/5
Total (%) 19/25 (76)e 0/14 (0) 0/15 (0) 2/20 (10) 1/20 (5) 0/22 (0)
aFraction of mice surviving tumor-free after 10 weeks post s.c. tumor cell injection. 5 · 105 CT26 or 2 · 105 MC38 tumor cells were
injected in 50 ml of HBSS in the right flank. Resulting tumor nodules were followed by weekly inspection and diameters recorded.
bCultured BM-derived DC or fibroblasts were infected with the indicated recombinant adenovirus at a MOI of 3000, 15 h before their
intratumoral injection. In vitro infection was carried out for 1 h in serum-free RPMI 1640 at room temperature and followed by a 14-h
incubation in RPMI 1640 5% FCS at 37 ° C.
cTumor nodules were slowly injected at day 8 after tumor cell inoculation with the indicated cells in 50 ml of HBSS using a 29 G needle.
dThe fibroblast cell line IZA2.1 was derived from adherent cells of healthy Balb/C livers by transfection with a plasmid encoding for
SV40 large T Ag (Melero I et al, manuscript in preparation).
ex2 test found this group different from the others with a P , 0.01.
ND, not done.
blasts were required for the antitumor effect beyond the
mere transduction with IL-12 genes. It has been reported
that fibroblasts retrovirally engineered to secrete IL-12
were efficacious upon peritumoral injection in other
tumor models, but at doses at least 10 times higher than
the ones used in this study.27 Autologous DC transfected
with control AdCMVlacZ, or untransfected, displayed a
marginal antitumor effect within the range of doses used
in these experiments. In the case of tumor nodules treated
with AdCMVIL-12 transduced syngeneic DC, the malig-
nant masses started to regress several days (5 to 10) after
the procedure (data not shown), as if the antitumor effec-
tor mechanisms required this period of time to generate
a curative response.
Because CT26 tumors were successfully treated in most
instances by a single dose of 2 · 105 IL-12-producing DC,
it was not considered an adequate model to optimize the
therapeutic regimen although injections of larger doses
of 106 IL-12-engineered DC seem to achieve better anti-
tumor efficacy according to our preliminary data (I
Melero et al, unpublished observations). With MC38,
which is only cured in half of the cases, we are currently
exploring potential improvements in the overall anti-
tumor effect using higher and/or repeated intratumoral
doses of IL-12-transduced BM-derived DC. It is note-
worthy that the level of IL-12 secreted seems to play an
important role since in the case of a batch of DC secreting
10 times less IL-12 due to a mistake in the MOI of
AdCMVIL-12 used for gene transfer only a very marginal
antitumor effect was observed (data not shown).
Cellular requirements for the induction of CT26 tumor
regression were studied by selective in vivo depletion
with specific anti-CD4 and anti-CD8 mAbs (Figure 2).
Both CD4+ and CD8+ T cells seemed to play a role since
only simultaneous depletion completely abrogated the
antitumor effect of IL-12-engineered DC injected into the
tumor, with eight of eight tumors progressing under
these conditions, while only two of eight progressed in
the non-depleted control group. Single CD8 depletion
partially impaired the antitumor effect (six of eight
tumors progressed), whereas CD4 depletion by itself did
not impair or even improve the antitumor effect (none of
eight tumors progressed). Such results in this tumor
model are consistent with observations obtained in stud-
ies using immunotherapy with tumor antigen-pulsed on
DC,19 which showed a crucial role for both CD8 and CD4
subsets during induction of immunity and only for CD8+
T cells during the effector phase. In our case CD4
depletion by itself did not affect tumor regressions indi-
cating that IL-12 gene transduction into DC might be par-
tially bypassing the need for CD4 help in CTL generation.
Nevertheless the data obtained upon simultaneous CD4
and CD8 depletion may point to a beneficial involvement
of CD4 cells in the overall elicited antitumor effect, which
could explain the elimination of the observed residual
antitumor activity after single CD8 depletion.
Paraffin-embedded CT26 tumor sections obtained on
days 4 and 7 after intratumoral injection of IL-12-engine-
ered DC were examined upon staining with hematoxylin
and eosin and compared with untreated tumors. Treated
tumors show a marked mononuclear infiltrate and abun-
dant areas of intense necrosis. Granulocytes are also seen
in much smaller numbers surrounding necrotic areas.
Frozen samples of the same tumors were analyzed by
immunostaining showing that the majority of tumor
infiltrating mononuclear cells were CD8+ CD4- but a
small contribution of CD4+ cells to the infiltrate could be
detected (data not shown). These data are in agreement
with the in vivo depletion experiments.
Memory in the immune mechanisms was found when
mice who had rejected a tumor nodule 10 weeks earlier
upon treatment with AdCMVIL-12-infected DC,
remained tumor-free after a second lethal challenge in the
opposite flank with tumor cells which aggressively pro-
gressed in naive, sex- and age-matched mice (Figure 3).
These data also indicated that the procedure has induced
systemic immunity against tumor cells which can be
therapeutically useful to prevent the outgrowth of
micrometastasis. In this regard, mice who carried s.c.
CT26 tumors bilaterally were able to reject both tumor
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Figure 2 T-lymphocytes are required for the antitumor effect of intratu-
moral injections of BM-derived DC infected with AdCMVIL-12. Individ-
ual size evolution of the tumor nodules in Balb/c mice injected subcutane-
ously with 5 · 105 CT26 cells. Seven days later, and weekly thereafter,
mice were injected i.p. with 100 ml of HBSS (control) or ascites fluid of
the anti-CD4 (GK15), anti-CD8 (53.6.72), or both hybridomas as indi-
cated. Tumor nodules in every group were injected with 2.5 · 105 BM-
derived DC infected with AdCMVIL12 (MOI, 3000) at day 9 after tumor
inoculation. High titer ascites fluid was produced by i.p. injection of the
hybridomas in Balb/c nude mice. Four control mice were injected with
100 ml of each ascites and depletion of the corresponding lymphocyte sub-
sets was found to be complete 1 day later upon immunostaining and FACS
analysis of the relevant populations in the spleen of these mice as
described.26 5–9-week-old male mice Balb/c, C57Bl/6, and Balb/cnude/nude
were purchased from Charles River (Barcelona, Spain) and housed in our
animal facility according to institutional guidelines. The hybridomas
GK15 and 53.6.72 were obtained through ATCC; CT26 was obtained from
Dr K Brand (Max Plank-Institut fur Biochemie, Germany) and MC38
from Dr Lieping Chen (Bristol Myers Squibb, Seattle, WA, USA). Cell
lines grown in DMEM 10% FCS from GIBCO (Basel, Switzerland). For
tumor follow-up, opposite maximal tumor nodule diameters were meas-
ured weekly with a precision calliper until mice spontaneously died or
were killed when nodules surpassed 25 mm or when they developed
severe ulceration.
nodules in six of eight cases when only one of the nod-
ules received intratumoral injection of 106 IL-12-engine-
ered DC, whereas all tumors progressed bilaterally in a
control group (n = 8) identically intratumorally injected
in one of the nodules but with non-transduced DC (data
not shown).
It was observed that intratumoral injection of IL-12-
transduced DC induced CTL specific for CT26 without
cytolytic activity against P815 and YAC-1 cells (Figure 4).
In addition, we took advantage of the fact that CT26
expresses a tumor rejection antigen named AH1.28 This
Figure 3 Rejection of CT26 tumors after intratumoral injection with
AdCMVIL-12 infected DC induces long-lasting systemic antitumor
immunity. Mice (n = 4) who have rejected a primary CT26 tumor after
intratumoral injection of 2.5 · 105 BM-derived DC infected with
AdCMVIL-12 were rechallenged s.c. 10 weeks later with a dose of 5 · 105
CT26 viable cells on the opposite flank. As a control, naive littermates
(n = 4) were also injected with a similar dose of CT26. Tumor development
and size – s.d. were monitored weekly in the area of the tumor rechallenge.
Similar mice which had rejected CT26 tumors after intratumoral injection
of BM-derived DC infected with AdCMVIL-12 developed lethal malig-
nancies when s.c. rechallenged with A20 lymphoma cells indicating
tumor-specificity of the protection (data not shown).
epitope has been identified as a 8-mer peptide presented
by H-2Ld, derived from the env gene of a retroviral
sequence silent in the genome of cells from normal
Balb/c mice, but expressed in CT26 cells. CTL cultured
from mice whose tumor nodules had been injected with
IL-12-transduced DC showed specificity for this epitope
pulsed on P815 cells (H-2d) (Figure 4). Bearing in mind
these data and the current view on the physiology of
DC,1–3 we postulate a model in which artificially injected
IL-12-transduced DC pick up tumor antigens during a
transient residence in the malignant tissue and become T
cell stimulators after migration into lymphoid tissues.29
This would be consistent with the fact that BM-derived
DC have been shown to acquire tumor antigens upon in
vitro coculture with a tumor cell line without further
manipulation.30 In this regard, it is of interest that DC
are very efficient at internalizing apoptotic bodies31,32 and
maybe they take up antigen from compartments of the
tumor nodule undergoing programmed cell death. We
are in the process of investigating whether pretreatment
of the tumor with agents increasing apoptosis enhance
antigen transfer and presentation in our model. It is also
conceivable that mechanical effects of injection of fluid
into the experimental tumor facilitate release and capture
of intracellular antigens. However direct demonstration
in this system of tumor antigen capture and transport
into T cell areas of lymphoid tissue by the injected DC is
the aim of our current and future research. It is note-
worthy that our defective recombinant adenovirus have
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Figure 4 Intratumoral injection with BM-derived DC infected with
AdCMVIL-12 induces tumor-specific CTLs. Cytolytic activity in 4 h 51Cr-
release assays of CTL cultures derived from three pooled spleens of CT26
tumor-bearing Balb/c treated on day 7 after tumor inoculation with BM-
derived DC infected with AdCMVIL-12 and harvested 7 days later was
measured against 51Cr-labelled CT26, P815 and YAC-1 cells at different
effector:target ratios. When indicated P815 targets were pulsed with 10
mm of AH1 (SPSYVYHQF) or control P1AB (LPYLGWLVF) peptides
during the assay. Results are representative of two independent experi-
ments. 51Cr-release assays were performed as described.42 CTL cultures
were raised by a 5-day coculture of spleen cell suspensions harvested 7
days after intratumoral injection of IL-12 producing DC with non-viable
CT26 cells in RPMI 1640 10% FCS.42 YAC-1 and P815 were from
ATCC. Peptide synthesis was performed as described.28,43
a deletion in the E3 region so infection does not interfere
with the MHC class I antigen presenting pathway.22,26
If the scenario of local antigen uptake and following
migration through lymphatic vessels holds true, IL-12
secreted by DC will be a potent stimulator of Th1 cells
and CTL precursors33,34 upon arrival in T cell areas of
draining lymph nodes. In addition, IL-12 secreted at the
tumor site may downregulate angiogenesis35 or mediate
other antitumor effects, although these mechanisms must
be secondary under our conditions because neither IL-
12-transfected allogeneic DC nor fibroblasts mediate any
measurable antitumor effect. More importantly, IL-12 has
been shown to act in an autocrine fashion on DC promot-
ing maturation and migration of DC through the acti-
vation of NFkB transcription factors.36 In fact, culture of
DC with exogenous recombinant IL-12 induces the
secretion of endogenous IL-12 conferring DC with the
ability to prime CTL responses.37 According to these
reports, part of the IL-12 detected in our transfected DC
could result from the activation of endogenous IL-12
genes in a positive autocrine feed-back. In addition, it has
also been reported that spleen mononulear cells or pur-
ified B cells pulsed with a defined murine tumor antigen
can induce protective immunity only if recombinant IL-
12 is coinjected into the footpad.38 Although only protec-
tive but not therapeutic immunity is seen in that model,
it would be interesting to understand the role of rIL-12
in enhancing the immunostimulatory properties of DC or
other APCs. Moreover, our preliminary data suggest that
at least part of the effects seen after transduction of DC
by AdCMVIL-12 are mediated by IL-12 in an autocrine
fashion (Galofre JC et al, manuscript in preparation).
In conclusion, the reported therapeutic effect of intratu-
moral injections with AdCMVIL-12 infected DC might
have clinical application for a number of reasons: (1) it
does not require the identification of tumor antigens; (2)
it can be done in every patient provided that DC can be
cultured from peripheral blood; (3) avoids the toxicity of
systemic doses of IL-12,39 which have been used to
enhance immunotherapy with DC.38 The advantage in
our approach is that IL-12 is presumably secreted at the
precise site of antigen presentation and lymphocyte acti-
vation. Although clinical feasibility of these kinds of pro-
cedures awaits further safety experimentation, we have
not observed any noticeable side-effect in animals
rejecting their tumors. In this regard, the potential
appearance of immunity against normal components of
the injected tissue should be carefully evaluated.40 It will
also be important to study comparatively the efficacy of
this new approach with other means to use DC in tumor
immunotherapy in different tumor models, including
those which propose the use of DC transfected with
other cytokines.41
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